Luke V Selby1, Emily A Vertosick2, Daniel D Sjoberg2, Mark A Schattner3, Yelena Y Janjigian4, Murray F Brennan1, Daniel G Coit1, Vivian E Strong5. 1. Department of Surgery, Gastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Department of Medicine, Gastroenterology and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY. 5. Department of Surgery, Gastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: strongv@mskcc.org.
Abstract
BACKGROUND: Surgical quality improvement requires well-defined benchmarks and accurate reporting of postoperative adverse events, which have not been well defined for total gastrectomy. STUDY DESIGN: Detailed postoperative outcomes on 238 patients who underwent total gastrectomy with curative intent, from 2003 to 2012, were reviewed by a dedicated surgeon chart reviewer to establish 90-day patterns of adverse events. RESULTS: Of the 238 patients with stage I to III gastric adenocarcinoma who underwent curative-intent total gastrectomy, the median age was 66 years, and 68% were male. Median body mass index was 28 kg/m(2), and 68% of patients had at least 1 medical comorbidity. Forty-three percent of our patients received neoadjuvant chemotherapy, and 34% received postoperative adjuvant chemotherapy. Over the 90-day study period, 30-day mortality was 2.5% (6 of 238), and 90-day mortality was 2.9% (7 of 238). At least 1 postoperative adverse event was documented in 62% of patients, with 28% of patients experiencing a major adverse event requiring invasive intervention. The readmission rate was 20%. Anemia was the most common adverse event (20%), followed by wound complications (18%). The most common major adverse event was esophageal anastomotic leak, which required invasive intervention in 10% of patients. CONCLUSIONS: This analysis has defined comprehensive 90-day patterns in postoperative adverse events after total gastrectomy with curative intent in a Western population. This benchmark allows surgeons to measure, compare, and improve outcomes and informed consent for this surgical procedure.
BACKGROUND: Surgical quality improvement requires well-defined benchmarks and accurate reporting of postoperative adverse events, which have not been well defined for total gastrectomy. STUDY DESIGN: Detailed postoperative outcomes on 238 patients who underwent total gastrectomy with curative intent, from 2003 to 2012, were reviewed by a dedicated surgeon chart reviewer to establish 90-day patterns of adverse events. RESULTS: Of the 238 patients with stage I to III gastric adenocarcinoma who underwent curative-intent total gastrectomy, the median age was 66 years, and 68% were male. Median body mass index was 28 kg/m(2), and 68% of patients had at least 1 medical comorbidity. Forty-three percent of our patients received neoadjuvant chemotherapy, and 34% received postoperative adjuvant chemotherapy. Over the 90-day study period, 30-day mortality was 2.5% (6 of 238), and 90-day mortality was 2.9% (7 of 238). At least 1 postoperative adverse event was documented in 62% of patients, with 28% of patients experiencing a major adverse event requiring invasive intervention. The readmission rate was 20%. Anemia was the most common adverse event (20%), followed by wound complications (18%). The most common major adverse event was esophageal anastomotic leak, which required invasive intervention in 10% of patients. CONCLUSIONS: This analysis has defined comprehensive 90-day patterns in postoperative adverse events after total gastrectomy with curative intent in a Western population. This benchmark allows surgeons to measure, compare, and improve outcomes and informed consent for this surgical procedure.
Authors: Stephen R Grobmyer; Fredric M Pieracci; Peter J Allen; Murray F Brennan; David P Jaques Journal: J Am Coll Surg Date: 2007-03 Impact factor: 6.113
Authors: Pierre A Clavien; Jeffrey Barkun; Michelle L de Oliveira; Jean Nicolas Vauthey; Daniel Dindo; Richard D Schulick; Eduardo de Santibañes; Juan Pekolj; Ksenija Slankamenac; Claudio Bassi; Rolf Graf; René Vonlanthen; Robert Padbury; John L Cameron; Masatoshi Makuuchi Journal: Ann Surg Date: 2009-08 Impact factor: 12.969
Authors: Nabil P Rizk; Peter B Bach; Deborah Schrag; Manjit S Bains; Alan D Turnbull; Martin Karpeh; Murray F Brennan; Valerie W Rusch Journal: J Am Coll Surg Date: 2004-01 Impact factor: 6.113
Authors: David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua Journal: N Engl J Med Date: 2006-07-06 Impact factor: 91.245
Authors: Vivian E Strong; Ai-Wen Wu; Luke V Selby; Mithat Gonen; Meier Hsu; Kyo Young Song; Cho Hyun Park; Daniel G Coit; Jia-Fu Ji; Murray F Brennan Journal: J Surg Oncol Date: 2015-07-14 Impact factor: 3.454
Authors: Luke V Selby; Daniel D Sjoberg; Danielle Cassella; Mindy Sovel; Martin R Weiser; Kent Sepkowitz; David R Jones; Vivian E Strong Journal: J Surg Res Date: 2015-03-06 Impact factor: 2.192
Authors: Jeremy L Davis; Luke V Selby; Joanne F Chou; Mark Schattner; David H Ilson; Marinela Capanu; Murray F Brennan; Daniel G Coit; Vivian E Strong Journal: Ann Surg Oncol Date: 2016-01-05 Impact factor: 5.344
Authors: Allison N Martin; Deepanjana Das; Florence E Turrentine; Todd W Bauer; Reid B Adams; Victor M Zaydfudim Journal: J Gastrointest Surg Date: 2016-06-30 Impact factor: 3.452